Navigation Links
NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
Date:1/25/2008

Anticipates Full Year 2007 Revenue of Approximately $154 million Announces Full Year 2008 Revenue Guidance of $204 Million to $208 Million

and Reiterates Marginal GAAP Profitability

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, today announced preliminary unaudited financial results for the full year ended December 31, 2007 and provided financial guidance for the full year 2008.

NuVasive anticipates full year 2007 revenue of approximately $154 million. The Company announced anticipated full year 2007 revenue in advance of its National Sales Meeting, which will take place January 25-26, 2008. NuVasive's previously announced guidance for 2007 non-GAAP earnings remains unchanged.

NuVasive also announced revenue guidance for the full year 2008. The Company expects full year 2008 revenue to be in the range of $204 million to $208 million and reiterated its previous guidance of marginal GAAP profitability.

NuVasive will not be holding a conference call to discuss its preliminary unaudited full year 2007 financial results. The Company will announce complete financial and operating details of its fourth quarter and full year ended December 31, 2007 after the market closes on February 19, 2008 and hold a conference call at 5:30 p.m. ET (2:30 p.m. PT).

Alex Lukianov, Chairman and Chief Executive Officer, said, "We are very pleased with the Company's performance in 2007 and look forward to recognizing and rewarding our top performers at this week's National Sales Meeting. We remain on track to meet our long-term goal of mid-30% revenue growth rate over the next several years."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product p
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...udy released this week showing that a growing numb...c diseases shines a much-needed spotlight on the n...at focuses on primary and secondary prevention, ac... disease prevention. , , (Logo: http://www...., , The study, conducted by Social & Scient...
(Date:1/8/2009)...chle at his confirmation hearing to be the next Se...SHINGTON, Jan. 8 Bipart...ator Tom Daschle, nominee for Department of Health...ellow BPC founder and friend Senator Bob Dole at h...vened by the Senate Health, Education, Labor, and ...
(Date:1/8/2009)...earch Hospital have demonstrated a more effective ...nza. They found that the antibiotics clindamycin a... their protein synthesis, are more effective than ...tam" antibiotic ampicillin, which causes the bacte...ant because pneumonia, rather than the influenza i...
(Date:1/8/2009)...re-FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN...t and chief,executive officer, will present at th...n Wednesday, January 14, at 10:00 a.m. Pacific Tim...o. , Dr. Hung will provide an overview of M...or Dimebon for Alzheimer,s and Huntington,s diseas...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...ine has been shrouded in controversy. Now, Britain...alled for an end to the raging //debates over this...public that warns of a threat to young lives by fo...They have appealed to the politicians, healthcare ...
...lison, a University of Alabama biostatistician has...ons for obesity. //He was assisted in this venture...da and Italy. The researchers looked at more than... besides exercise and diet. They found that the fo...
... is on the rise in New Zealand. Hence Pharmac deci...se who have serious fluctuations in blood sugar le...r Lantus at a subsidized rate from July 1. Murra... the Diabetes New Zealand said that they have work...
...rays of women with high-risk genes could increase ...archers led by David Goldgar // at the Internation...d 1,600 women. He found that women with BRCA1 and ... mutations who had undergone a chest X-ray were 54...
Other Medicine News:
(Date:1/3/2009)... , , , , ROSEMONT, Ill., Jan. 2...ging (MRI) is a growing technology providing an in...the evaluation of back pain according to an articl...American Academy of Orthopaedic Surgeons ( http://...ext several years, additional technical developmen...
(Date:12/29/2008)...BETHESDA, Md., Dec. 29 ...an Research Protection was announced today by Dr. ... Health Improvement Institute. , , The winner ... M.D. Anderson Cancer Center -- for its best pr...This program provides for 1) enhanced human subjec...
(Date:12/27/2008)... SAN DIMAS, Calif., Dec. 27 Acc...ers are best advised to consume modest doses of,r...as typically provided in 3,to 5 glasses of aged, ...(Photo: http://www.newscom.com/cgi-bin/prnh/2008...ws mega-dose resveratrol alone fails to prolong,t...
(Date:12/17/2008)...ificant milestone met in development and validatio... ASHLAND, Mass., Dec. 17 MatTek C...ic Advisory Committee (ESAC) endorsed the scientif...n Test (SIT) at its November meeting. ESAC conclu...ccuracy and reliability for the prediction of skin...
Breaking Medicine Technology:MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 32008 Human Research Protection Award Recipients Announced 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 1Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 5MIT solves gravity defying bird beak mystery 3337 1MIT solves gravity defying bird beak mystery 3337 2MIT solves gravity defying bird beak mystery 3337 3UC San Diego nanostructures will raise thin film solar cell efficiency 5463 1UC San Diego nanostructures will raise thin film solar cell efficiency 5463 2Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 1Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 2Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 3
...abasis Therapeutics,Inc. (Nasdaq:MBRX), a biophar...opment and commercialization of novel drugs for th...lying unique,capabilities for targeting the liver ...rs were presented at the Endocrine Society,s,89th ...rovide data on MB07811, the Company,s,liver-target...
...able to two widely used diabetes medicines , , ...n 33,000 type 2 diabetes patients in a real-world,... the incidence of,hospitaliations for heart attack...rization for patients on Avandia is the,same as ...ere,released in a paper titled “Coronary Hea...
Other Medicine Technology:Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 2Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 3Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 4Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
...ECHET EXTENDER® is a new device for skin exten... elastomer strips, it allows a constant and powerf...r devices capacities. Such effectiveness makes the...it is removed before 30 days. Furthermore it is in...
Inquire
Inquire
Medicine Products: